For Authors

Manuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication elsewhere, except in the form of an abstract. Prior abstract publications should be described in the form of a footnote to the article title. Published manuscripts become the sole property of the Journal and will be copyrighted by Mary Ann Liebert, Inc.

Upon acceptance of any manuscript, EACH author listed on a paper will receive a follow-up email with instructions to complete the online Copyright Agreement form. It is critical to ensure the accuracy of ALL authors’ email addresses when uploading submissions to Manuscript Central to ensure the proper delivery of all email communications, particularly the Copyright Agreement.

FAILURE BY ALL AUTHORS TO SUBMIT THIS FORM WILL RESULT IN A DELAY IN PUBLICATION.

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy(formerly Hybridoma) will publish both full and short communications. Full communications should be prepared in the format described below; short communications do not need compartmentalization and should be limited to a maximum of two tables or two figures or one of each. Authors will be allowed to indicate one reviewer who should be excluded from review of their manuscript. The Journal also includes MONOCLONAL ANTIBODIES. This section provides prompt publication of current information on new hybrid cell lines, methodology, and other information arising from the use of monoclonal antibodies.

Page charges for this journal are set at $65.00 USD per typeset page. Nonpayment of page charges may result in a delay in publication. Costs for printing images in color are a separate fee and are not included in the page charge total.

Be sure these instructions are followed exactly.

Prepare manuscripts double-spaced in Microsoft Word. Leave ample margins on the sides, top, and bottom of the page. TABLES AND ILLUSTRATIONS. Prepare each table with its title on a separate page. Use Arabic numerals to number tables. Remember, each table must stand alone, i.e., contain all necessary information in the caption, and the table itself must be understood independently of the text. Details of experimental conditions should be included in the table footnotes. Information that appears in the text should not be repeated in tables, and tables should not contain data that can be given in the text in one or two sentences. All illustrations should be numbered and labeled with the first author’s name. A legend should be supplied for each illustration, and all legends numbered consecutively and provided (double-spaced) on a separate page. Figures should be numbered in the order cited in the text. Images should not show the name of the manufacturer. Please keep in mind that the figures will be reduced, so please do not submit large figures/graphs that contain small type, as the text within the figure will not be readable after reduction.

Please follow these instructions when submitting figures:

Do not include any illustrations as part of your text file.

Do not prepare any figures in Word as they are not workable.

Line illustrations must be submitted at a minimum of 900.

Halftones and color photos should be submitted at a minimum of 300 DPI.

PowerPoint of Excel files cannot be uploaded.

Save art as either TIFF or EPS files. Do NOT submit JPEG files.

You will be given directions on how to correct any files which do not pass.

ADDITIONAL INFORMATION ABOUT ART FILES

Converting Word or Excel files: Perhaps the best and easiest way to convert Word or Excel files into a format which is suitable for print is to scan them using the below guidelines:

All files should be scanned at 100% size. 300 dpi Final color mode: cmyk save file as: .tif or .eps

All authors are expected to disclose any institutional or commercial affiliations that might pose a conflict of interest regarding the publication of a manuscript. Institutional affiliations, as indicated on the title page, should include all corporate affiliations and any funding sources that support the work. Other types of affiliation, including consultantships, honoraria, stock ownership, equity interests, arrangements regarding patents, or other vested interests should be disclosed in the Acknowledgments section.

REFERENCES All references must be cited in text. (1) Cite references within the text by an Arabic number within parentheses or brackets. Brackets may be used when parentheses are to be reserved for numbers for equations. (2) List references by numbers (1., 2., etc.) in the order in which they appear in the text. Type double spaced, although separated from each other by one line of space. (3) Use Chemical Abstracts format for references. For journal citations: (1) surname of author(s), initials, (2) paper title, (3) journal, (4) volume number, (5) first and last page of citation, and (6) year in parentheses. For book citations: (1) surname of author(s), initials, (2) title of book, (3) editor of book (if applicable), (4) edition of book (if applicable), (5) publisher, (6) city of publication, (7) year of publication (not in parentheses), and (8) first and last page reference (if applicable). For patents: (1) country of original registration, (2) patent number, (3) month, day, and year of issuance. Follow the style of these examples:

When data from an unpublished source are given, supply complete information, e.g., researcher's name and location. If work is in press, give journal in which it is to be published or publisher.

PERMISSIONS The author must obtain permission to reproduce figures, tables, and text from previously published material. Written permission must be obtained from the original copyright holder (generally the publisher, not the author or editor) of the journal or book concerned. An appropriate credit line should be included in the figure legend or table footnote, and full publication information should be included in the reference list. Written permission must be obtained from the author of any unpublished material cited from other laboratories, and should accompany the manuscript. All permission listings must be shown in manuscript-they cannot be entered on proofs.

PAGE PROOFSOnce a paper is accepted, changes in authorship in page proofs are NOT permitted under any circumstance.

It is the Journal’s policy that a manuscript has only ONE corresponding author listed on a paper. This designation should be determined at the time of submission. Additions to corresponding authors are not permitted after acceptance or in page proofs.

Page proofs will be sent to the (one) corresponding author as designated when the manuscript was uploaded to Manuscript Central. It is the corresponding author’s responsibility to share the page proofs with co-authors and to coordinate all authors’ corrections into one proof. The Publisher will not accept corrections from multiple authors.

REPRINTS Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.

Does your research funder have an open access mandate or would you like to expand the dissemination of your research?

The Liebert Open Access option allows authors to publish open access in our esteemed subscription-based journals.

The benefits of Liebert Open Access include:

- High visibility; open access articles are freely available online upon publication

- You retain copyright with the open access license allowing broad dissemination of your research

- You can freely share your article in repositories and research networks without restrictions

- Easy compliance with open access mandates

- Rigorous editorial and peer-review

- Targeted email announcement featuring a direct link to article

Identification and Marketing Open access articles are listed with an OA icon in journal tables of content (TOC), TOC alerts, and in marketing announcements. Open access articles are highlighted and promoted in targeted email announcements to thousands of research leaders in your field.

Copyright and Licensing If you choose to publish with open access, you will retain copyright of your article and a Creative Commons license will be applied. The liberal Creative Commons Attribution 4.0 (CC-BY) license is the default open access license used at Mary Ann Liebert Publishers. The CC-BY license permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

At this time we allow authors to choose between the CC-BY or CC-BY-NonCommercial license. A limited number of journals offer NonCommercial licenses exclusively.

Ordering Open Access Once your article has been accepted for publication in a journal, you will receive an email with information on ordering Liebert Open Access. If you would like more information about Liebert Open Access or would like to order open access, please email openaccess@liebertpub.com.

Publishing open access includes an article publication charge (APC) and authors are asked to fill out a short open access order form. You can pay by credit card or receive an invoice to be returned with payment or via bank transfer. Please remember that traditional subscription journals can carry mandatory or optional author fees. The Liebert Open Access APC does not cover or replace existing publication or author fees.

Publishing biomedical or biotechnology research?Biomedical researchers should consider publishing inBioResearch Open Access, a fully open access peer-reviewed journal dedicated to publishing top research in the biomedical and biotechnology fields. For details, please visit the information for authors on the journal website.

*Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.

Is your Institution a member of the Liebert Author Advocacy Program?

The Liebert Author Advocacy Program (LAAP)provides valuable membership benefits for OA publication to institutional and funding organizations, and supports global funding mandates. Authors who are affiliated with LAAP member institutions receive all the valuable benefits of Liebert OA article publication, and more.

NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.

Publishing in Subscription Journals

By signing the copyright transfer statement, authors still retain a set of rights that allow for self-archiving.

Authors may archive their preprint manuscripts (version prior to peer review) at any time without restrictions. Authors may archive their postprint manuscripts (accepted version after peer review) in institutional repositories, preprint servers, and research networks after a 12 month embargo. The 12-month embargo period begins when the article is published online. Postprints must not be used for commercial purposes and acknowledgement must be given to the final publication, and publisher, by inserting the DOI number of the article in the following sentence: “Final publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/[insert DOI]”. Authors may archive on their personal website without an embargo provided their manuscript is updated with an acknowledgement to the publisher copyright and final published version.

The final published article (version of record) can never be archived in a repository, preprint server, or research network.

Publishing Open Access

Authors that wish to easily comply with funder or institutional open access mandates should consider publishing open access. Liebert Open Accessoption allows authors to make their research freely available online without restrictions. Additionally, Liebert Open Access option allows authors to retain copyright, archive and share the final published version of their article without restrictions. To publish open access please email openaccess@liebertpub.com or visit Liebert Open Access for more information.

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.

Recommended Publications

AIDS Research and Human Retroviruses

The leading journal in the field for over 25 years, providing the latest developments and research advances in HIV/AIDS and other retroviruses leading to improvements in translational medicine for optimal treatment outcomes.

Cancer Biotherapy and Radiopharmaceuticals

The established journal with over 25 years of peer-reviewed papers on new and innovative investigations of methods to improve cancer therapy. The Journal focuses on advancements in radioimmunotherapy and radiopharmaceuticals.

DNA and Cell Biology

Combining mechanistic and clinical studies from multiple systems in a single resource, the Journal delivers authoritative, peer-reviewed reporting on the latest research in the field of molecular biology.

Human Gene Therapy

The definitive rapid-publication journal covering all aspects of gene therapy through original investigations into the transfer and expression of genes in mammals, with in-depth coverage of DNA, RNA, and cell therapies.

Viral Immunology

The only journal reporting on all aspects of the rapidly growing field of viral immunology, with comprehensive coverage of immune responses to viral infections from basic mechanisms to clinical applications.